R3 Stem Cell Achieves IRB Approval for Umbilical Cord Cell Therapy Study

SCOTTSDALE, Ariz., April 1, 2019 /PRNewswire-PRWeb/ -- R3 Stem Cell, the nation's leader in regenerative therapies, has now achieved IRB approval for an amniotic and umbilical cord cell therapy study. The study is the only institutional review board approved protocol now in the United States.

The study, which is patient funded and industry subsidized, involves seven different condition categories including musculoskeletal, cardiac, renal, pulmonary, neurologic, autoimmune and urologic. Patients who are over the age of 18 may be included in the study, with only a few exclusion criteria.

With seven different condition categories involved, patients may receive therapy for quite a lot of medical conditions such as arthritis, COPD, neuropathy, kidney failure, post-stroke, rheumatoid arthritis, erectile dysfunction, congestive heart failure and more.

Currently, there are over ten study Centers in the United States, with more on the way. Patients receive stem cell procedures with first rate biologics that include several protocols including injection, IV, intranasal and nebulizer depending on the condition category.

"It is critical to acquire data on outcomes with regenerative therapies. R3 has done over 10,000 successful stem cell procedures to date nationwide, and now we are the ONLY company to have achieved IRB approval for our protocols! We are excited for patients to be a part of our study and standardize outcome data to further the field of regenerative medicine," said CEO David Greene, MD, MBA.

Patients who would like to be considered for study inclusion should call (844) GET-STEM or visit https://r3stemcell.com. The study is patient funded, so they do pay for the procedures. For medical practices that would like to be under the IRB, the same number should be called.

SOURCE R3 Stem Cell

Related Links

https://r3stemcell.com